Fulgent Genetics, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 1, 2025 and accepted by EDGAR at Aug 1, 2025, 07:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $81.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $155.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $47.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $92.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $34.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $62.8m | us-gaap:GrossProfit |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $13.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $25.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$19.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$39.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $17.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $31.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-04-01 to 2025-06-30 | −$2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | −$2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$19.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$30.5m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 30,544,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 30,687,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$34.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $11.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2025-01-01 to 2025-06-30 | $10.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-06-30 | $87.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $428.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $1.20bn | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $71.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $88.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $1.12bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-101105. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.